212
Participants
Start Date
June 12, 2018
Primary Completion Date
June 14, 2020
Study Completion Date
June 14, 2020
ZYN002 - Cannabidiol Transdermal Gel
Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
Placebo Transdermal Gel
Placebo formulated as a clear gel (transdermal delivery)
Westmead Children's Hospital, Sydney
Genetics Clinics Australia, Melbourne
Lady Cilento Children's Hospital - South Brisbane, Brisbane
Wellington Hospital, Wellington
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics, New York
Suburban Research Associates, Media
Kennedy Krieger Institute, Baltimore
University of North Carolina, Chapel Hill
Greenwood Genetic Center, Greenville
Emory University School of Medicine, Atlanta
University Hospitals Cleveland Medical Center, Cleveland
Cincinnati Children's Hospital Medical Center, Cincinnati
Rush University Medical Center, Chicago
Central States Research, Tulsa
Children's Hospital of Colorado, Denver
Southwest Autism Research and Resource Center, Phoenix
Phoenix Children's Hospital, Phoenix
UC Davis Health System, MIND Institute, Sacramento
University of Washington Center for Human Development and Disability, Seattle
Boston Children's Hospital, Boston
Fragile X Center of Atlantic Health System, Morristown
Zynerba Pharmaceuticals, Inc.
INDUSTRY